ALLMedicine™ Mantle Cell Lymphoma Center

May 30th, 2021 - Zanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatoto...

May 24th, 2021 - MicroRNAs (miRNAs) with functional relevance have not been previously identified in mantle cell lymphoma (MCL). Here, we aimed to evaluate the relationships between miR-34a and miR-155-5p and MCL clinicopathology and prognosis. Seventy-five paraff...

May 18th, 2021 - Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate of of molecular markers. Therefor...

May 18th, 2021 - Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We ...

May 18th, 2021 - The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of t...

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial...

Jan 6th, 2019 - In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our f...

May 16th, 2018 - Guideline for the management of mantle cell lymphoma.|2018|McKay P,Leach M,Jackson B,Robinson S,Rule S,|therapeutic use,prevention & control,methods,pathology,therapy,

Sep 8th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

May 30th, 2021 - Zanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatoto...

May 24th, 2021 - MicroRNAs (miRNAs) with functional relevance have not been previously identified in mantle cell lymphoma (MCL). Here, we aimed to evaluate the relationships between miR-34a and miR-155-5p and MCL clinicopathology and prognosis. Seventy-five paraff...

May 18th, 2021 - Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate of of molecular markers. Therefor...

May 18th, 2021 - Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We ...

May 18th, 2021 - The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of t...

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

Sep 9th, 2020 - Dr Eduardo Sotomayor Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and which should receive aggressive t...